User: prashantiyengar Topic: IP
Category: drugs :: india
Last updated: Oct 02 2014 08:01 IST RSS 2.0
 
1 to 20 of 2,428    
Pharmaceutical companies refute Congress' post claiming hike in prices of life-saving drugs 2.10.2014 ET: Pharma
Novartis, which owns patent for Glivec globally but excluding India, and Natco Pharma, whose generic version of drug was also listed on website.
Also found in: [+]
Modi must resist U.S. pressure on drug patents - MSF 30.9.2014 Sify Finance
Also found in: [+]
Industrial policy repair 30.9.2014 Telegraph: Opinion
After having his fill of sushi, the prime minister is back home and in the saddle, and has renewed his campaign to revive industry. This is a departure from his predecessor's approach of laissez faire. Another change is that Narendra Modi has invited manufacturers from abroad to come and make things in India. That is a bit surprising. His party has always believed in Little India. Indian industrialists have been its supporters; they cannot be enthusiastic about competition from foreigners bringing the latest technology and building brand new factories in India. But Modi must have done his political homework; let me concentrate on how best he can achieve his aim.
Also found in: [+]
Will Modi bow to US pressure to modify India’s pro-people patent law? 23.9.2014 TOI: India
A large number of civil society groups and public intellectuals have issued a public statement expressing concern over the government’s decision to review India’s positions on intellectual property ...
Also found in: [+]
Intellectual Property Rights and India's competitiveness 22.9.2014 ET: Policy
According to the most recent IP Index by GIPC of the US Chamber of Commerce, India's rank is the last among 25 countries for which the Center prepares the Index.
Also found in: [+]
IPR and India's competitiveness (Column: Active Voice) 22.9.2014 Sify Finance
. They also have an impact on the FDI inflows in a developing country, which helps not just in terms of capital inflows, but also in terms of technology and expertise. Strengthening IPR thus becomes imperative from the viewpoint of economic development. According to the most recent IP Index by GIPC (Global Intellectual Property Center) of the US Chamber of Commerce, India's rank is the last among 25 countries for which the Center prepares the Index. It is alarming, and steps need to be taken to ensure we do better on various aspects covered under the specific index.
Also found in: [+]
Irritants on Modi itinerary 21.9.2014 Telegraph: Business
New Delhi, Sept. 21: Prime Minister Narendra Modi's trip to the US later this week will give the Obama administration an opportunity to not only woo an important ally in Asia but also take up issues ranging from India's pharma patent regime to its stand at the World Trade Organization.
Also found in: [+]
Cipla teams up with Gilead Lifesciences to make Hepatitis drug for MNC 17.9.2014 ET: Pharma
On the face of it, there is nothing wrong with this kind of a deal. Pharma companies ink many such pacts on a regular basis.
Also found in: [+]
Hepatitis C drug in India to cost 49 lakh less than in US 16.9.2014 ET: Pharma
The voluntary licencing deal promises to make the drug cheap in India as well as up to 91 countries where the Indian firms are allowed to sell it.
Also found in: [+]
Pill for thought: Sweetheart deals that hurt consumers 16.9.2014 Rediff: Top Stories (India)
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
Also found in: [+]
Epirus, Ranbaxy win India approval for arthritis drug copy 16.9.2014 ET: Pharma
Epirus Biopharmaceuticals Inc said India's drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the country early next year.
Also found in: [+]
Hepatitis C drug in India to cost 49 lakh less than in US 16.9.2014 TOI: India
Sofosbuvir, the wonder medicine for Hepatitis C that costs $84,000 or Rs 50.4 lakh for a 24-week treatment regimen in the US, will soon be available in India for about $1,800 or roughly Rs 1.1 lakh for the same ...
Also found in: [+]
Hope for 'cheap' hepatitis drug 16.9.2014 Telegraph: Nation
New Delhi, Sept. 15: A US biopharmaceutical company today announced its move to make available a medicine to treat hepatitis C virus infections in India and 90 other developing countries at prices much lower than the treatment-course cost of $84,000 (Rs 51.3 lakh) in the US.
Also found in: [+]
Government to hear out US pharma companies' patent fears 15.9.2014 ET: Pharma
The meeting itself is the fallout of discussions by a committee of secretaries, where it was felt that the government should engage with the companies.
Also found in: [+]
Pfizer, Ranbaxy win dismissal of lawsuit over generic Lipitor 13.9.2014 Sify Finance
Also found in: [+]
US drug patent expiries to benefit Indian pharma industry 10.9.2014 DNA: Popular News
Expiry of drug patents in the US is great news for not only consumers but also the domestic pharmaceutical industry, where generics account for about 75 per cent of total sales, CARE Ratings said in its report released here today. Indian pharmaceutical companies have an opportunity to capitalise on the patent cliff and gain a greater share of the growing generics market. At present, India accounts for nearly 40 per cent of generic drugs, over-the-counter products and 10 per cent of finished dosages used in the US. During 2014-2016, about USD 92 billion worth of patented drugs are expected to go off-patent in the USA as compared to USD 65 billion during 2010-12. Indian companies' share in the US generics market has grown rapidly on the back of aggressive Abbreviated New Drug Application (ANDA) filings, successful pursuit of Para-IV and capitalisation on patent expiries of blockbuster drugs. Under US laws, ANDA filed with a Para-IV certification states that the generic company which is the first-to-file a ...
Also found in: [+]
IPR policy on the cards to protect national interests, says Nirmala Sitharaman 9.9.2014 ET: Policy
The US is threatening to downgrade India’s intellectual property environment in an out-of-cycle review expected shortly.
Also found in: [+]
IPR policy in the works 9.9.2014 Telegraph: Business
New Delhi, Sept. 8: The government plans to come out with a policy on intellectual property rights (IPR) within a few months, with developed nations such as the US and the EU raising concerns over the country's patent rules.
Also found in: [+]
Poly Medicure wins long patent battle against German pharma giant B Braun 8.9.2014 ET: Pharma
This could also bolster its case in some of the other European jurisdictions where it is defending patent infringement suits from the German giant.
Also found in: [+]
Lack of initiative in drug discovery ails India: Dhaval Kumar Patel, Novartis 2.9.2014 ET: Healthcare
One of the biggest concerns about India, according to Patel, is that the country is still way behind others in global advancements made in science.
Also found in: [+]
1 to 20 of 2,428